Celebrex, Bextra Given Breathing Room In Latest FDA Advisory

Agency suggests any regulatory action on COX-2s or non-selective NSAIDs will wait until after a February advisory committee meeting. A public health advisory urges physicians to consider the “emerging” information on cardiovascular risk when prescribing COX-2s. FDA also orders a review of all prevention studies using Pfizer’s Celebrex and Bextra.